Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644460 · ClinicalTrials.gov registry record · Phase 1
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02644460 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 53 participants.
The verdict
NCT02644460, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant brain (Grade III/IV, including DIPG; MBT) and solid tumor (ST) patients (Stratum B).
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-02 |
| Est. Completion | 2023-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02644460
The ClinicalTrials.gov registry entry for NCT02644460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT02644460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02644460 about?
NCT02644460 is a clinical study titled "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors". This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant brain (Grade III/IV, ...
What is the current status of trial NCT02644460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2016-02. Estimated completion is 2023-10-10.
What interventions are being tested in trial NCT02644460?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT02644460?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.